Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus platinum-doublet chemotherapy as neoadjuvant therapy for potentially resectable stage IIIB NSCLC
ChiCTR2000040673Phase 2Recruiting
- Sponsor
- Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Shenzhen Hospital, Cancer Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Major pathologic response. Started Dec 2020; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000040673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040673.